Document Detail


The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
MedLine Citation:
PMID:  9331015     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study was performed to evaluate the antihypertensive efficacy and tolerability of candesartan cilexetil 8-16 mg once-daily in comparison with placebo in elderly hypertensive patients. Forty-one hospital and general practice centres in the Netherlands and in the United Kingdom enrolled 350 patients over 65 years of age with essential hypertension (WHO grades I or II). Patients with supine diastolic BP in the range 95-114 mm Hg after 4- to 8-week placebo run-in period (n = 193) were randomised to double-blind therapy with candesartan cilexetil or placebo. The initial dose of candesartan cilexetil 8 mg or placebo was doubled after 6 weeks if supine diastolic blood pressure (BP) exceeded 90 mm Hg. Mean (95% confidence interval) placebo-corrected reduction in supine diastolic BP after 12 weeks' treatment with candesartan cilexetil was 7.5 mm Hg (3.6-11.4; P < 0.001); the corresponding reduction in supine systolic BP was 13.6 mm Hg (6.9-20.2; P < 0.001). Placebo-corrected mean reduction in supine diastolic BP 2 and 4 h after the first dose of candesartan cilexetil were 2.2 mm Hg (-1.3 to +5.8; P = 0.219) and 4.0 mm Hg (-0.4 to +7.6; P = 0.027), respectively. Candesartan cilexetil had almost no influence on heart rate and did not affect the normal orthostatic changes in BP. Adverse events were equally common in the two treatment groups. Candesartan cilexetil 8-16 mg once-daily is an effective antihypertensive agent in elderly patients. The onset of action is smooth with no exaggerated response after the first dose and there is no postural hypotension. Candesartan cilexetil is very well tolerated in elderly hypertensives.
Authors:
G T McInnes; K P O'Kane; J Jonker; J Roth
Related Documents :
20653455 - Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure cont...
12435255 - Effect of blood pressure lowering and antihypertensive drug class on progression of hyp...
6345835 - Improvement in hypertension detection and control from 1973-1974 to 1980-1981. the minn...
22662095 - A laplace pressure based microfluidic trap for passive droplet trapping and controlled ...
1741685 - Absence of lung reactions after complement depletion during dialysis: an experimental s...
19571825 - Cold stimulation induces different responses of ophthalmic artery blood flow velocity d...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of human hypertension     Volume:  11 Suppl 2     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1997-11-06     Completed Date:  1997-11-06     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S75-80     Citation Subset:  IM    
Affiliation:
University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiotensin Receptor Antagonists*
Antihypertensive Agents / therapeutic use*
Benzimidazoles / adverse effects,  therapeutic use*
Biphenyl Compounds / adverse effects,  therapeutic use*
Blood Pressure / drug effects
Double-Blind Method
Female
Heart Rate / drug effects
Humans
Hypertension / drug therapy*,  physiopathology
Male
Patient Compliance
Tetrazoles*
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Tetrazoles; R85M2X0D68/candesartan cilexetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hyper...
Next Document:  Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension.